Semaglutide Oral Formulation Reduces Cardiovascular Risk in Type 2 Diabetes Patients
A new phase 3b trial found that the oral formulation of semaglutide, a GLP-1 receptor agonist, reduces the risk for major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease or chronic kidney disease. The study, SOUL, involved over 9,650 patients and showed a 14% relative reduction in cardiovascular death, … Read more